The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction.


OBJECTIVE Peroxisome proliferator-activated receptor gamma (PPARgamma) activators may be beneficial in heart failure due to their metabolic and antihypertrophic effects, but these agents can cause oedema. We hypothesized that, on balance, the PPARgamma activator rosiglitazone would be beneficial in heart failure post-myocardial infarction. METHODS AND… (More)


  • Presentations referencing similar topics